CHAPTER 69 Liver Transplantation
1 What is the Model for End-stage Liver Disease MELD?
The Model for End-stage Liver Disease (MELD) is a scoring system for prioritizing patients for liver transplantation. The MELD score is an objective model that predicts a patient’s 90-day mortality while waiting for a liver transplant. It is a better predictor of perioperative mortality than the Child’s scoring system and therefore has replaced it. MELD is calculated using bilirubin, international normalized ratio, and creatinine (the MELD calculator can be accessed at www.UNOS.org). There are four listing status categories for patients with liver disease:


2 Describe some indications and contraindications for liver transplantation
Indications for liver transplantation include end-stage liver disease from hepatocellular disease, cholestatic disease, vascular disease, or polycystic disease. In addition, some nonresectable hepatic malignancies, metabolic liver diseases, and fulminant hepatic failure are indications (Table 69-1). Over time relative and absolute contraindications for liver transplantation have evolved (Table 69-2). Because MELD predicts 3-month survival, those with the highest scores have the greatest chance of dying from liver disease and thus have the best risk-benefit ratio for undergoing liver transplantation.
TABLE 69-2 Contraindications to Liver Transplantation
AIDS, Acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
Modified from Maddrey WC, Van Thiel DH: Liver transplantation: an overview, Hepatology 8:948, 1988.
3 How does the cardiovascular physiology of a patient with end-stage liver disease differ from that of a normal patient?
5 What is the significance of portal pulmonary hypertension? How are these patients managed in the pretransplant period?
6 What are the concerns before anesthetic induction in the patient with end-stage liver disease?





7 Describe the three stages of liver transplantation


9 List some of the anesthetic concerns during the preanhepatic (dissection) phase






12 Describe some of the major anesthetic management issues during the reperfusion stage (stage 3)





KEY POINTS: Liver Transplantation
13 What are indicators of graft function during stage 3?

1. Baker J., Yost S., Niemann C. Organ transplantation. In: Miller R.D., editor. Anesthesia. ed 6. Philadelphia: Churchill Livingstone; 2005:2231-2283.
2. Csete M., Glas K. Anesthesia for organ transplantation. In: Barash P., editor. Clinical anesthesia. ed 5. Philadelphia: Lippincott William & Wilkins; 2006:1364-1367.
3. Krenn C., De Wolf A. Current approach to intraoperative monitoring in liver transplantation. Curr Opin Organ Transplant. 2008;13(3):285-290.